Methamphetamine addiction is growing national public health problem, yet to date there are no approved pharmacological treatments for this disorder. In recent years, animal studies have demonstrated that the type 5 metabotropic glutamate receptor (mGluR5) is involved in various aspects of experimental addiction. For example, mice lacking mGluR5 receptors do not self-administer cocaine and are indifferent to its locomotor stimulant effects. Similarly, selective mGluR5 antagonists (also known as negative allosteric modulators) reduce the reinforcing effects of cocaine, heroin, nicotine, and alcohol in rodents and/or non-human primates. Selective mGluR5 antagonists also reduce relapse-like behavior in these species, are currently being tested in Phase I and II clinical trials for the treatment of other medical conditions including depression, anxiety, migraine, gastroesophageal reflux disease, and Fragile X Syndrome. Thus far, these compounds appear to be well tolerated by human subjects with no serious adverse side effects. We have generated encouraging preliminary data in rats that the selective mGluR5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) dose-dependently reduces intravenous methamphetamine self-administration, breakpoints for methamphetamine on a progressive ratio schedule of reinforcement, as well as reinstatement of methamphetamine-seeking behavior elicited by drug-associated cues and drug priming. These effects of MTEP are not likely due to a generalized inhibition of behavioral output, since we have observed that MTEP does not alter food self-administration, breakpoints for food on a progressive ratio schedule of reinforcement, or cue-induced reinstatement of food-seeking behavior. These data support our overall hypothesis that mGluR5 antagonists may be novel pharmacological agents for use in the treatment of methamphetamine addiction. In the present application, we propose additional preclinical medications development studies to further explore the potential utility of mGluR5 antagonists in the treatment of addiction to methamphetamine. Specifically, we propose to examine the effects of MTEP and the clinically validated mGluR5 antagonist fenobam in rodent models of methamphetamine addiction that more closely resemble patterns of human methamphetamine use (prolonged daily self-administration and binge-abstinent patterns of intake).
In Specific Aim 1, we will test the hypothesis that selective mGluR5 antagonists will reduce the reinforcing effects of methamphetamine following escalation of intake produced by extended drug access.
In Specific Aim 2, we will test the hypothesis that selective mGluR5 antagonists will attenuate the increases in the reinforcing efficacy of methamphetamine observed following binge-abstinent patterns of self-administration. Together, these medications development studies will provide a preclinical basis for the use of mGluR5 antagonists in the treatment of methamphetamine addiction in humans.

Public Health Relevance

The goal of this proposal is to provide a preclinical basis for the potential use of mGluR5 antagonists for the treatment of methamphetamine addiction. Should such compounds eventually prove to be effective in the treatment of methamphetamine addiction in humans, this would represent a major public health advancement and would significantly reduce the medical, socioeconomic and legal costs of this disorder to society.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA025606-04
Application #
8286401
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
White, David A
Project Start
2009-08-01
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
4
Fiscal Year
2012
Total Cost
$283,793
Indirect Cost
$91,733
Name
Arizona State University-Tempe Campus
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
943360412
City
Tempe
State
AZ
Country
United States
Zip Code
85287
Taylor, S B; Anglin, J M; Paode, P R et al. (2014) Chronic stress may facilitate the recruitment of habit- and addiction-related neurocircuitries through neuronal restructuring of the striatum. Neuroscience 280:231-42
Watterson, Lucas R; Olive, M Foster (2014) Synthetic cathinones and their rewarding and reinforcing effects in rodents. Adv Neurosci (Hindawi) 2014:209875
Lewis, Candace R; Olive, M Foster (2014) Early-life stress interactions with the epigenome: potential mechanisms driving vulnerability toward psychiatric illness. Behav Pharmacol 25:341-51
Blum, Kenneth; Foster Olive, M; Wang, Kevin K W et al. (2013) Hypothesizing that designer drugs containing cathinones ("bath salts") have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. Med Hypotheses 81:450-5
Watterson, Lucas R; Watterson, Elizabeth; Olive, Michael Foster (2013) Abuse liability of novel 'legal high' designer stimulants: evidence from animal models. Behav Pharmacol 24:341-55
Kufahl, Peter R; Watterson, Lucas R; Nemirovsky, Natali E et al. (2013) Attenuation of methamphetamine seeking by the mGluR2/3 agonist LY379268 in rats with histories of restricted and escalated self-administration. Neuropharmacology 66:290-301
Watterson, Lucas R; Kufahl, Peter R; Nemirovsky, Natali E et al. (2013) Attenuation of reinstatement of methamphetamine-, sucrose-, and food-seeking behavior in rats by fenobam, a metabotropic glutamate receptor 5 negative allosteric modulator. Psychopharmacology (Berl) 225:151-9
Cleva, Richard M; Watterson, Lucas R; Johnson, Meagan A et al. (2012) Differential Modulation of Thresholds for Intracranial Self-Stimulation by mGlu5 Positive and Negative Allosteric Modulators: Implications for Effects on Drug Self-Administration. Front Pharmacol 2:93
Olive, M Foster; Cleva, Richard M; Kalivas, Peter W et al. (2012) Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 100:801-10
Olive, M Foster (2010) Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur J Pharmacol 639:47-58